Soleno Therapeutics Inc (NASDAQ:SLNO) Reports Q2 2025 Earnings Beat with Strong VYKAT™ XR Launch Performance

Soleno Therapeutics Inc (NASDAQ:SLNO) reported its second-quarter 2025 financial results alongside an update on the U.S. launch of its lead product, VYKAT™ XR. The company’s earnings and revenue figures diverged from analyst expectations, prompting a notable market reaction.

Key Financial Highlights vs. Estimates

• Revenue: Soleno posted Q2 revenue of $32.66 million, significantly surpassing the consensus estimate of $25.64 million. This represents a 27.4% beat on sales expectations.
• Earnings Per Share (EPS): The company reported a loss of $0.09 per share, a substantial improvement compared to the estimated loss of $0.47 per share.

The strong revenue performance suggests robust early adoption or execution in the commercialization of VYKAT™ XR, while the narrower-than-expected loss indicates better cost management or higher-than-anticipated sales contributions.

Market Reaction

Following the earnings release, Soleno’s stock saw an after-hours gain of 1.23%, reflecting investor optimism about the revenue beat and improved earnings. However, the stock has struggled in recent weeks, with declines of -2.79% over the past week, -5.10% over two weeks, and -4.26% over the past month, possibly due to broader market conditions or pre-earnings caution.

Analyst Estimates for Future Performance

Looking ahead, analysts project:

• Q3 2025 Revenue: $36.67 million (estimated)
• Full-Year 2025 Revenue: $111.45 million (estimated)
• Full-Year 2025 EPS: -$3.20 (estimated)

The company did not provide explicit guidance in its press release, making it difficult to assess whether these estimates align with internal expectations. However, the Q2 outperformance could lead to upward revisions if sustained.

Press Release Summary

The earnings update also included commentary on the U.S. launch of VYKAT™ XR, Soleno’s treatment for Prader-Willi syndrome (PWS). While specific sales figures were not disclosed, the revenue beat suggests early traction. The company emphasized its focus on rare disease therapeutics, with VYKAT™ XR holding Breakthrough Therapy and Fast-Track designations in the U.S., as well as Orphan Drug status in both the U.S. and EU.

For a deeper dive into Soleno’s earnings and future estimates, view the full breakdown here.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research before making any financial decisions.